Holen Sie sich die Stockscreener-App
55.89
0.98%
-0.8158
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
IONS Maintained by Barclays -- Price Target Lowered to $85.00 - GuruFocus
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News
IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Ionis Pharmaceuticals gets $85 price target des... - Pluang
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com
Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander DiseaseSlideshow (NASDAQ:IONS) 2026-09-07 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment - Yahoo
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Zacks Investment Research
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Evaluating A 51.72% Upside Potential - DirectorsTalk Interviews
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) - BioSpace
Ionis wins FDA approval for Zilganersen to treat Alexander disease - Indian Pharma Post
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines - BioPharma Dive
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $61 to $115 - Moomoo
Novartis’ pelacarsen fails Phase 3 trial, missing cardiovascular risk reduction endpoint - Minichart
Six first-in-class approvals in August - BioCentury
Novartis, Ionis’ experimental heart drug misses key goal in closely watched trial - WTVB
FDA Grants Approval for Ionis Pharmaceuticals' ZANVASTRO to Treat Alexander Disease - Kalkine Media
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - quiverquant.com
Ionis Stock Loses $877 Million After Pelacarsen Phase 3 Miss - TechStock²
FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease - MedCity News
Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome - TipRanks
Ionis Pharmaceuticals Reports Pelacarsen Phase 3 Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint - Kalkine Media
Ionis, Novartis’ key experimental heart drug fails in late-stage trial - 1470 & 100.3 WMBD
Ionis, Novartis' key experimental heart drug fails in late-stage trial - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
Ionis-Novartis heart drug misses main goal of late-stage trial - marketscreener.com
Ionis Wins FDA Nod for First-Ever Alexander Disease Therapy, Priced at $285,000 a Dose - finance.biggo.com
Ionis Pharmaceuticals Price Target Maintained With a $115.00/Share by HC Wainwright & Co. - Moomoo
Ionis: Downgrading To Sell After A Series Of Unfortunate Events (NASDAQ:IONS) - Seeking Alpha
FDA Approves Ionis’s Zanvastro for Alexander Disease - Financial-News.co.uk
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. - Barron's
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment - Yahoo Finance
Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval - Endpoints News
FDA Approves Ionis ASO Zanvastro for Alexander Disease From Infancy - GenomeWeb
World to conquer: Alexander FDA nod turns Ionis to diagnostics - BioWorld News
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro - The Globe and Mail
Ionis Pharmaceuticals Inc. (IONS) Peer Comparison – Compare with Others - Value Research
H.C. Wainwright reiterates Ionis stock rating on Zanvastro approval By Investing.com - Investing.com UK
Why Did Ionis Pharmaceuticals (IONS) Stock Drop After Its Latest Update? - Yahoo Finance
IONS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $115 - GuruFocus
Ionis wins FDA approval for ZANVASTRO in Alexander disease - TipRanks
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal - Yahoo Finance
ZANVASTRO™ (zilganersen) approved by the FDA as the first and onl - The National Law Review
IONIS PHARMACEUTICALS, INC. : JEFFERIES CUTS TARGET PRICE TO $88 FROM $90 - Moomoo
Ionis Pharmaceuticals (IONS) Gains First-Mover Advantage with FDA Approval of Rare Brain Disease Drug - Yahoo Finance
Ionis Pharma’s drug becomes first FDA-approved treatment for rare brain disorder - KELO-AM
IONS Looks 20.8% Overvalued on GF Value™ After FDA Approval for Zanvastro - GuruFocus
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients - Post Register
Ionis gains approval of zilganersen for Alexander disease (NASDAQ:IONS) - Seeking Alpha
US FDA approves Ionis Pharma’s therapy to treat rare brain disorder - 1470 & 100.3 WMBD
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial - Yahoo Finance
IONS Looks 20.8% Overvalued on GF Value™ - GuruFocus
US FDA approves Ionis Pharma's therapy to treat rare brain disorder - TradingView
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):